A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant gain of 39.44% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 59.07%. Over the past 30 days, the price of PCRX has fallen by 13.72%. And in the last five days, it has surged by 9.14%.
Pacira BioSciences Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $31.67 on 05/17/24, while the lowest value for the same period was recorded at $11.16 on 08/13/24.
52-week price history of PCRX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Pacira BioSciences Inc’s current trading price is -17.05% away from its 52-week high, while its distance from the 52-week low is 135.31%. The stock’s price range during this period has varied between$11.16 and $31.67. The Pacira BioSciences Inc’s shares, which operate in the Healthcare, saw a trading volume of around 3.72 million for the day, a figure considerably higher than their average daily volume of 0.87 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Pacira BioSciences Inc (PCRX) has experienced a quarterly rise of 41.01% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.22B and boasts a workforce of 790 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 22.05, with a change in price of +8.77. Similarly, Pacira BioSciences Inc recorded 855,455 in trading volume during the last 100 days, posting a change of +50.11%.
PCRX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for PCRX stands at 0.82. Similarly, the long-term debt-to-equity ratio is also 0.55.
PCRX Stock Stochastic Average
Pacira BioSciences Inc’s raw stochastic average for the past 50 days is presently 76.58%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 76.58%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 45.14% and 46.98%, respectively.
